Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2020 07:00 ET | Source: Karyopharm Therapeutics Inc.

U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration...
July 17, 2020 07:00 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative...
July 14, 2020 07:00 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch -- NEWTON,...
July 01, 2020 16:05 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
June 24, 2020 07:00 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology

NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL...
June 22, 2020 11:25 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular...
June 12, 2020 07:00 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting

NEWTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that eight posters relating to XPOVIO®...
June 09, 2020 09:00 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

NEWTON, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2...
June 01, 2020 16:05 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
May 28, 2020 16:05 ET | Source: Karyopharm Therapeutics Inc.

Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

-- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly...